Document is current

Article History

Received: 5 March 2024

Accepted: 13 August 2025

First Online: 2 September 2025

Declarations

:

: This systematic literature review did not require ethics approval or consent to participate. The information used in this review was reported in published articles and reported in the aggregate.

: P.A. has received honoraria from Janssen, Roche, Genmab, BMS, AbbVie, Incyte, Regeneron Pharmaceuticals, Inc., BeiGene, and AstraZeneca. A.J.U. has received honoraria from Regeneron Pharmaceuticals, Inc., Gilead Kite, Eli Lilly, AbbVie, Janssen, Sandoz, Roche, and Incyte. A.S and I.Z report no conflicts of interest. Y.K., J.U., M.S., L.W., E.T., K.C., and E.R. are employees of IQVIA, Inc. Q.M., J.J.J., A.N.A., Y.X., Sh.A., Sr.A., H.M., and C.H. are employees of Regeneron Pharmaceuticals, Inc. M.S. was supported by the National Institutes of General Medical Sciences (NIGMS) grant T32GM-075766 from 2019 to 2022 while at the University of Pennsylvania Perelman School of Medicine and received an International Society for Pharmacoepidemiology (ISPE) grant scholarship in 2022. These funding bodies had no role in the design and conduct of this study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the abstract; or the decision to submit for publication. B.v.T is an advisor or consultant for Allogene, Amgen, Bristol Myers Squibb/Celgene, Cerus, Gilead Kite, Incyte, IQVIA, Lilly, Merck Sharp & Dohme, Miltenyi, Novartis, Noscendo, PentixaPharm, Pfizer, Pierre Fabre, QualWorld, Roche, Sobi, and Takeda; has received honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb/Celgene, Gilead Kite, Incyte, Lilly, Merck Sharp & Dohme, Novartis, Roche Pharma AG, and Takeda; reports research funding to institution from Esteve, Merck Sharp & Dohme, Novartis, and Takeda; and reports travel support from AbbVie, AstraZeneca, Gilead Kite, Lilly, Merck Sharp & Dohme, Novartis, Pierre Fabre, Roche, and Takeda.